October 28, 2010
Barcelona, October, 2010 – BCN Peptides and DiverDrugs, two biopharmaceutical companies specialized in peptides, announced positive preclinical results of their candidate for cancer pain, chronic pain and other inflammatory pain conditions and their intention to conduct Phase I clinical trials. Press release DD04107
July 30, 2010
On July 2010, BCN Peptides has received the Accreditation as Foreing Drug Manufacturer from Japanese MHLW.
April 15, 2010
Since March 2010, BCN Peptides has been authorised by the Spanish Health Authorities to work as Pharmaceutical Laboratory for the analysis of Final Pharmaceutical Product. With this License we can offer to our customers the possibility to perform the Analytical development, validations and tests both for the release and for the stability Studies of Final Pharmaceutical Product.